A new DNA vaccine targeting p62 has shown promising results in alleviating chronic inflammation and osteoporosis by exploiting the protein's role in autophagy. The vaccine, currently in phase I clinical trials, may offer a safe treatment for inflammatory bone loss.
A protein sequence associated with Huntington's disease has been identified as a potential life-saving vaccine component. The polyQ-based adjuvant efficiently enhances both branches of the immune response to a poor model antigen, with no apparent toxicity in mice.
Cure Lab, Inc. has developed a new technology that combines two forms of vaccine antigens: one easily processed by the proteosome and another resistant to it. This combination elicits a stronger immune response than using either form alone, promising improved vaccine efficiency.
Scientists at Cure Lab, Inc. have identified a new target for the development of anti-influenza drugs, specifically the M2 protein, which may be responsible for killing human cells. This discovery has the potential to lead to a new generation of medicines that can complement existing treatments for influenza.